JPMorgan analyst Jessica Fye points out that Amgen's (AMGN) romosozumab, while meeting the co-primary and secondary endpoints, did not reduce the incidence of non-vertebral fractures at either 12 or 24 months. The drug seems effective and reasonably well tolerated but does not appear superior to Radius Health's (RDUS) abaloparatide, Fye tells investors in a research note after Amgen announced Phase III results for its drug. She maintains an Overweight rating on Radius and expects sentiment for the company to improve. The stock is up 27%, or $7.00, to $34.00 in early trading.